Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
This study has been completed.
Study NCT00227266 Information provided by University of Utah
First Received: September 23, 2005 Last Updated: December 23, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Spinal Muscular Atrophy
Additional conditions recognized in this trial
Atrophy
Muscular Atrophy
Muscular Atrophy, Spinal
More general conditions related to this trial
Central Nervous System Diseases
Motor Neuron Disease
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Neuromuscular Diseases
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Signs and Symptoms
Spinal Cord Diseases
Interventions listed in this trial
Valproic Acid and Levocarnitine
Additional drug interventions recognized in this trial
Carnitine
Valproic Acid
More general drug interventions related to this trial
Anticonvulsants
Antimanic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Vitamin B Complex
Vitamins
Sponsors listed in this trial
University of Utah
Families of Spinal Muscular Atrophy
Sigma Tau Pharmaceuticals, Inc.
Abbott
Back to top of Main Content
